24 results on '"Tögel L"'
Search Results
2. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
- Author
-
Janning, M., primary, Süptitz, J., additional, Albers-Leischner, C., additional, Delpy, P., additional, Tufman, A., additional, Velthaus-Rusik, J.-L., additional, Reck, M., additional, Jung, A., additional, Kauffmann-Guerrero, D., additional, Bonzheim, I., additional, Brändlein, S., additional, Hummel, H.-D., additional, Wiesweg, M., additional, Schildhaus, H.-U., additional, Stratmann, J.A., additional, Sebastian, M., additional, Alt, J., additional, Buth, J., additional, Esposito, I., additional, Berger, J., additional, Tögel, L., additional, Saalfeld, F.C., additional, Wermke, M., additional, Merkelbach-Bruse, S., additional, Hillmer, A.M., additional, Klauschen, F., additional, Bokemeyer, C., additional, Buettner, R., additional, Wolf, J., additional, Loges, S., additional, Simon, Ronald, additional, Sauter, Guido, additional, Volk, Alexander, additional, Neumann, Jens, additional, Klauschen, Frederick, additional, Weichert, Wilko, additional, Kalhori, Naser, additional, Lüthen, Reinhard, additional, Stöhr, Robert, additional, Schubart, Chistoph, additional, Wacker, Heidemarie, additional, Fuchs, Florian, additional, Hartmann, Nils, additional, Graf, Stefanie, additional, Brandts, Christian, additional, Wild, Peter, additional, Demes, Melanie, additional, Reis, Henning, additional, and Rohde, Gernot, additional
- Published
- 2022
- Full Text
- View/download PDF
3. DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis
- Author
-
Tögel, L, Nightingale, R, Wu, R, Chüeh, AC, Al-Obaidi, S, Luk, I, Dávalos-Salas, M, Chionh, F, Murone, C, Buchanan, DD, Chatterton, Z, Sieber, OM, Arango, D, Tebbutt, NC, Williams, D, Dhillon, A, Mariadason, JM, Tögel, L, Nightingale, R, Wu, R, Chüeh, AC, Al-Obaidi, S, Luk, I, Dávalos-Salas, M, Chionh, F, Murone, C, Buchanan, DD, Chatterton, Z, Sieber, OM, Arango, D, Tebbutt, NC, Williams, D, Dhillon, A, and Mariadason, JM
- Published
- 2018
4. 936P - Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC)
- Author
-
Eckstein, M., Hartmann, A., Strissel, P., Strick, R., Wach, S., Taubert, H., Wullich, B., Geppert, C., Weyerer, V., Stoehr, R., Rübner, M., Fasching, P.A., Rabizadeh, S., Benz, S., Haller, F., Moskalev, E., and Toegel, L.
- Published
- 2019
- Full Text
- View/download PDF
5. Correction: The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner (Journal of
- Author
-
Shin, J, Carr, A, Corner, GA, Tögel, L, Dávalos-Salas, M, Tran, H, Chueh, AC, Al-Obaidi, S, Chionh, F, Ahmed, N, Buchanan, DD, Young, JP, Malo, MS, Hodin, RA, Arango, D, Sieber, OM, Augenlicht, LH, Dhillon, Amardeep, Weber, TK, Mariadason, JM, Shin, J, Carr, A, Corner, GA, Tögel, L, Dávalos-Salas, M, Tran, H, Chueh, AC, Al-Obaidi, S, Chionh, F, Ahmed, N, Buchanan, DD, Young, JP, Malo, MS, Hodin, RA, Arango, D, Sieber, OM, Augenlicht, LH, Dhillon, Amardeep, Weber, TK, and Mariadason, JM
- Published
- 2015
6. The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like Factor 5 (KLF5)-defendent manner
- Author
-
Shin, J, Carr, A, Corner, GA, Tögel, L, Dávaos-Salas, M, Tran, H, Chueh, AC, Al-Obaidi, S, Chionh, F, Ahmed, N, Buchanan, DD, Young, JP, Malo, MS, Hodin, RA, Arango, D, Sieber, OM, Augenlicht, LH, Dhillon, Amardeep, Weber, TK, Mariadason, JM, Shin, J, Carr, A, Corner, GA, Tögel, L, Dávaos-Salas, M, Tran, H, Chueh, AC, Al-Obaidi, S, Chionh, F, Ahmed, N, Buchanan, DD, Young, JP, Malo, MS, Hodin, RA, Arango, D, Sieber, OM, Augenlicht, LH, Dhillon, Amardeep, Weber, TK, and Mariadason, JM
- Published
- 2014
7. Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center.
- Author
-
Tögel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K, Moskalev EA, Stöhr R, Agaimy A, Reis A, Wullich B, Mackensen A, Pavel M, Beckmann MW, Hartmann A, Fietkau R, Meidenbauer N, Haller F, and Spoerl S
- Abstract
Molecular Tumor Boards (MTBs) converge state-of-the-art next-generation sequencing (NGS) methods with the expertise of an interdisciplinary team consisting of clinicians, pathologists, human geneticists, and molecular biologists to provide molecularly informed guidance in clinical decision making to the treating physician. In the present study, we particularly focused on elucidating the factors impacting on the clinical translation of MTB recommendations, utilizing data generated from gene panel mediated comprehensive genomic profiling (CGP) of 554 patients at the MTB of the Comprehensive Cancer Center Erlangen, Germany, during the years 2016 to 2020. A subgroup analysis of cases with available follow-up data ( n = 332) revealed 139 cases with a molecularly informed MTB recommendation, which was successfully implemented in the clinic in 44 (31.7%) of these cases. Here, the molecularly matched treatment was applied in 45.4% ( n = 20/44) of cases for ≥6 months and in 25% ( n = 11/44) of cases for 12 months or longer (median time to treatment failure, TTF: 5 months, min: 1 month, max: 38 months, ongoing at data cut-off). In general, recommendations were preferentially implemented in the clinic when of high (i.e., tier 1) clinical evidence level. In particular, this was the case for MTB recommendations suggesting the application of PARP, PIK3CA, and IDH1/2 inhibitors. The main reason for non-compliance to the MTB recommendation was either the application of non-matched treatment modalities ( n = 30)/stable disease ( n = 7), or deteriorating patient condition ( n = 22)/death of patient ( n = 9). In summary, this study provides an insight into the factors affecting the clinical implementation of molecularly informed MTB recommendations, and careful considerations of these factors may guide future processes of clinical decision making.
- Published
- 2023
- Full Text
- View/download PDF
8. Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
- Author
-
Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, and Mariadason JM
- Published
- 2023
- Full Text
- View/download PDF
9. Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.
- Author
-
Lüke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spoerl S, Heudobler D, Sparrer D, Kaiser U, Keil F, Schubart C, Tögel L, Einhell S, Dietmaier W, Huss R, Dintner S, Sommer S, Jordan F, Goebeler ME, Metz M, Haake D, Scheytt M, Gerhard-Hartmann E, Maurus K, Brändlein S, Rosenwald A, Hartmann A, Märkl B, Einsele H, Mackensen A, Herr W, Kunzmann V, Bargou R, Beckmann MW, Pukrop T, Trepel M, Evert M, Claus R, and Kerscher A
- Abstract
(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the regional impact and the outreach component of MTBs; (2) Methods: we analyzed MTB patient data from four neighboring Bavarian tertiary care oncology centers in Würzburg, Erlangen, Regensburg, and Augsburg, together constituting the WERA Alliance. Absolute patient numbers and regional distribution across the WERA-wide catchment area were weighted with local population densities; (3) Results: the highest MTB patient numbers were found close to the four cancer centers. However, peaks in absolute patient numbers were also detected in more distant and rural areas. Moreover, weighting absolute numbers with local population density allowed for identifying so-called white spots-regions within our catchment that were relatively underrepresented in WERA MTBs; (4) Conclusions: investigating patient data from four neighboring cancer centers, we comprehensively assessed the regional impact of our MTBs. The results confirmed the success of existing collaborative structures with our regional partners. Additionally, our results help identifying potential white spots in providing precision oncology and help establishing a joint WERA-wide outreach strategy., Competing Interests: The authors declare no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
10. MET Amplification in Non-Small Cell Lung Cancer (NSCLC)-A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting.
- Author
-
Schubart C, Stöhr R, Tögel L, Fuchs F, Sirbu H, Seitz G, Seggewiss-Bernhardt R, Leistner R, Sterlacci W, Vieth M, Seidl C, Mugler M, Kapp M, Hohenforst-Schmidt W, Hartmann A, Haller F, and Erber R
- Abstract
In non-small cell lung cancer (NSCLC), approximately 1-3% of cases harbor an increased gene copy number (GCN) of the MET gene. This alteration can be due to de novo amplification of the MET gene or can represent a secondary resistance mechanism in response to targeted therapies. To date, the gold standard method to evaluate the GCN of MET is fluorescence in situ hybridization (FISH). However, next-generation sequencing (NGS) is becoming more relevant to optimize therapy by revealing the mutational profile of each NSCLC. Using evaluable n = 205 NSCLC cases of a consecutive cohort, this study addressed the question of whether an amplicon based NGS assay can completely replace the FISH method regarding the classification of MET GCN status. Out of the 205 evaluable cases, only n = 9 cases (43.7%) of n = 16 high-level MET amplified cases assessed by FISH were classified as amplified by NGS. Cases harboring a MET GCN > 10 showed the best concordance when comparing FISH versus NGS (80%). This study confirms that an amplicon-based NGS assessment of the MET GCN detects high-level MET amplified cases harboring a MET GCN > 10 but fails to detect the various facets of MET gene amplification in the context of a therapy-induced resistance mechanism.
- Published
- 2021
- Full Text
- View/download PDF
11. YAP1-MAML2-Rearranged Poroid Squamous Cell Carcinoma (Squamoid Porocarcinoma) Presenting as a Primary Parotid Gland Tumor.
- Author
-
Agaimy A, Stoehr R, Tögel L, Hartmann A, and Cramer T
- Subjects
- Eccrine Porocarcinoma genetics, Humans, Male, Oncogene Proteins, Fusion genetics, Parotid Neoplasms genetics, Squamous Cell Carcinoma of Head and Neck genetics, Sweat Gland Neoplasms genetics, YAP-Signaling Proteins, Young Adult, Adaptor Proteins, Signal Transducing genetics, Eccrine Porocarcinoma pathology, Parotid Neoplasms pathology, Squamous Cell Carcinoma of Head and Neck pathology, Sweat Gland Neoplasms pathology, Trans-Activators genetics, Transcription Factors genetics
- Abstract
Porocarcinoma (synonym: malignant eccrine poroma) is a rare aggressive carcinoma type with terminal sweat gland duct differentiation. The squamous variant of porocarcinoma is even less frequent and might be indistinguishable from conventional squamous cell carcinoma (SCC). We herein describe the first case of a carcinoma presenting as a primary parotid gland malignancy in a 24-year-old male without any other primary tumor. Total parotidectomy and neck dissection were performed followed by adjuvant chemoradiation. The patient remained alive and well 10 months after diagnosis. Histology showed keratinizing SCC infiltrating extensively the parotid gland with subtle poroid cell features. Oncogenic HPV infection was excluded by DNA-based testing. NGS analysis using the TruSight RNA fusion panel (Illumina) revealed a novel YAP1-MAML2 gene fusion. This gene fusion was reported recently in a subset of cutaneous porocarcinoma and poroma. This case of poroid SCC (or squamoid porocarcinoma) adds to the differential diagnosis of SCC presenting as parotid gland tumor and highlights the value of molecular testing in cases with unusual presentation.
- Published
- 2021
- Full Text
- View/download PDF
12. TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers.
- Author
-
Weyerer V, Eckstein M, Strissel PL, Wullweber A, Lange F, Tögel L, Geppert CI, Sikic D, Taubert H, Wach S, Wullich B, Hartmann A, Stoehr R, and Giedl J
- Subjects
- Biomarkers, Tumor genetics, DNA Mutational Analysis, Humans, Mutation genetics, Urinary Bladder Neoplasms pathology, Neoplasm Recurrence, Local genetics, Promoter Regions, Genetic genetics, Telomerase genetics, Urinary Bladder Neoplasms genetics
- Abstract
Background: Multifocal occurrence is a main characteristic of urothelial bladder cancer (UBC). Whether urothelial transformation is caused by monoclonal events within the urothelium, or by polyclonal unrelated events resulting in several tumor clones is still under debate. TERT promoter mutations are the most common somatic alteration identified in UBC. In this study, we analyzed different histological tissues from whole-organ mapping bladder cancer specimens to reveal TERT mutational status, as well as to discern how tumors develop., Methods: Up to 23 tissues from nine whole-organ mapping bladder tumor specimens, were tested for TERT promoter mutations including tumor associated normal urothelium, non-invasive urothelial lesions (hyperplasia, dysplasia, metaplasia), carcinoma in situ (CIS) and different areas of muscle invasive bladder cancers (MIBC). The mutational DNA hotspot region within the TERT promoter was analyzed by SNaPshot analysis including three hot spot regions (-57, -124 or -146). Telomere length was measured by the Relative Human Telomere Length Quantification qPCR Assay Kit., Results: TERT promoter mutations were identified in tumor associated normal urothelium as well as non-invasive urothelial lesions, CIS and MIBC. Analysis of separate regions of the MIBC showed 100% concordance of TERT promoter mutations within a respective whole-organ bladder specimen. Polyclonal events were observed in five out of nine whole-organ mapping bladder cancers housing tumor associated normal urothelium, non-invasive urothelial lesions and CIS where different TERT promoter mutations were found compared to MIBC. The remaining four whole-organ mapping bladders were monoclonal for TERT mutations. No significant differences of telomere length were observed., Conclusions: Examining multiple whole-organ mapping bladders we conclude that TERT promoter mutations may be an early step in bladder cancer carcinogenesis as supported by TERT mutations detected in tumor associated normal urothelium as well as non-invasive urothelial lesions. Since mutated TERT promoter regions within non-invasive urothelial lesions are not sufficient alone for the establishment of cancerous growth, this points to the contribution of other gene mutations as a requirement for tumor development.
- Published
- 2021
- Full Text
- View/download PDF
13. YAP1-NUTM1 Gene Fusion in Porocarcinoma of the External Auditory Canal.
- Author
-
Agaimy A, Tögel L, Haller F, Zenk J, Hornung J, and Märkl B
- Subjects
- Adult, Aged, 80 and over, Ear Canal pathology, Humans, Male, Oncogene Fusion, Oncogene Proteins, Fusion genetics, YAP-Signaling Proteins, Adaptor Proteins, Signal Transducing genetics, Ear Neoplasms genetics, Eccrine Porocarcinoma genetics, Neoplasm Proteins genetics, Nuclear Proteins genetics, Sweat Gland Neoplasms genetics, Transcription Factors genetics
- Abstract
Gene fusions involving the NUTM1 gene (NUT) represent defining genetic markers of a highly aggressive carcinoma type with predilection for the midline structures of children and young adults, hence the original description as NUT midline carcinoma. Recent studies have increasingly documented involvement of the NUTM1 gene in the pathogenesis of other entities as well. We herein describe two cases of auditory canal carcinomas with features of porocarcinoma, both harboring a newly described YAP1-NUTM1 gene fusion. Patients were males aged 28 and 82 years who presented with slowly growing lesions in the external auditory canal. Histologic examination showed monomorphic basaloid and squamoid cells arranged into organoid solid aggregates, nests, ducts, small cysts, and focal pseudocribriform pattern with variable mitotic activity, infiltrative growth, and focal squamous differentiation, particularly in the most superficial part of the tumor. Immunohistochemistry revealed consistent reactivity for CK5, p63 and SOX10 and diffuse aberrant expression of TP53. CK7 expression was limited to a few luminal ductal cells. The androgen receptor and S100 were negative. Next generation sequencing (TruSight RNA fusion panel, Illumina) revealed the same YAP1-NUTM1 gene fusion in both tumors, which was subsequently confirmed by NUT-FISH and the monoclonal anti-NUT antibody. These cases represent a novel contribution to the spectrum of NUT-rearranged head and neck malignancies. This adnexal carcinoma variant should not be confused with the highly lethal NUT carcinoma based on NUT immunoreactivity alone.
- Published
- 2020
- Full Text
- View/download PDF
14. Integrating Genomics and Clinical Data for Statistical Analysis by Using GEnome MINIng (GEMINI) and Fast Healthcare Interoperability Resources (FHIR): System Design and Implementation.
- Author
-
Gruendner J, Wolf N, Tögel L, Haller F, Prokosch HU, and Christoph J
- Subjects
- Humans, Decision Support Systems, Clinical standards, Delivery of Health Care methods, Genomics methods, Health Information Interoperability standards, Internet standards, Machine Learning standards
- Abstract
Background: The introduction of next-generation sequencing (NGS) into molecular cancer diagnostics has led to an increase in the data available for the identification and evaluation of driver mutations and for defining personalized cancer treatment regimens. The meaningful combination of omics data, ie, pathogenic gene variants and alterations with other patient data, to understand the full picture of malignancy has been challenging., Objective: This study describes the implementation of a system capable of processing, analyzing, and subsequently combining NGS data with other clinical patient data for analysis within and across institutions., Methods: On the basis of the already existing NGS analysis workflows for the identification of malignant gene variants at the Institute of Pathology of the University Hospital Erlangen, we defined basic requirements on an NGS processing and analysis pipeline and implemented a pipeline based on the GEMINI (GEnome MINIng) open source genetic variation database. For the purpose of validation, this pipeline was applied to data from the 1000 Genomes Project and subsequently to NGS data derived from 206 patients of a local hospital. We further integrated the pipeline into existing structures of data integration centers at the University Hospital Erlangen and combined NGS data with local nongenomic patient-derived data available in Fast Healthcare Interoperability Resources format., Results: Using data from the 1000 Genomes Project and from the patient cohort as input, the implemented system produced the same results as already established methodologies. Further, it satisfied all our identified requirements and was successfully integrated into the existing infrastructure. Finally, we showed in an exemplary analysis how the data could be quickly loaded into and analyzed in KETOS, a web-based analysis platform for statistical analysis and clinical decision support., Conclusions: This study demonstrates that the GEMINI open source database can be augmented to create an NGS analysis pipeline. The pipeline generates high-quality results consistent with the already established workflows for gene variant annotation and pathological evaluation. We further demonstrate how NGS-derived genomic and other clinical data can be combined for further statistical analysis, thereby providing for data integration using standardized vocabularies and methods. Finally, we demonstrate the feasibility of the pipeline integration into hospital workflows by providing an exemplary integration into the data integration center infrastructure, which is currently being established across Germany., (©Julian Gruendner, Nicolas Wolf, Lars Tögel, Florian Haller, Hans-Ulrich Prokosch, Jan Christoph. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 07.10.2020.)
- Published
- 2020
- Full Text
- View/download PDF
15. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
- Author
-
Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, Pfarr N, Siebolts U, Hummel M, Herold S, Andreas J, Zoche M, Tögel L, Rempel E, Maas J, Merino D, Stewart M, Zaoui K, Schlesner M, Glimm H, Fröhling S, Allen J, Horst D, Baretton G, Wickenhauser C, Tiemann M, Evert M, Moch H, Kirchner T, Büttner R, Schirmacher P, Jung A, Haller F, Weichert W, and Dietel M
- Subjects
- Biomarkers, Tumor genetics, Humans, Mutation, Reference Standards, Exome Sequencing, Lung Neoplasms genetics
- Abstract
Introduction: Tumor mutational burden (TMB) is a quantitative assessment of the number of somatic mutations within a tumor genome. Immunotherapy benefit has been associated with TMB assessed by whole-exome sequencing (wesTMB) and gene panel sequencing (psTMB). The initiatives of Quality in Pathology (QuIP) and Friends of Cancer Research have jointly addressed the need for harmonization among TMB testing options in tissues. This QuIP study identifies critical sources of variation in psTMB assessment., Methods: A total of 20 samples from three tumor types (lung adenocarcinoma, head and neck squamous cell carcinoma, and colon adenocarcinoma) with available WES data were analyzed for psTMB using six panels across 15 testing centers. Interlaboratory and interplatform variation, including agreement on variant calling and TMB classification, were investigated. Bridging factors to transform psTMB to wesTMB values were empirically derived. The impact of germline filtering was evaluated., Results: Sixteen samples had low interlaboratory and interpanel psTMB variation, with 87.7% of pairwise comparisons revealing a Spearman's ρ greater than 0.6. A wesTMB cut point of 199 missense mutations projected to psTMB cut points between 7.8 and 12.6 mutations per megabase pair; the corresponding psTMB and wesTMB classifications agreed in 74.9% of cases. For three-tier classification with cut points of 100 and 300 mutations, agreement was observed in 76.7%, weak misclassification in 21.8%, and strong misclassification in 1.5% of cases. Confounders of psTMB estimation included fixation artifacts, DNA input, sequencing depth, genome coverage, and variant allele frequency cut points., Conclusions: This study provides real-world evidence that all evaluated panels can be used to estimate TMB in a routine diagnostic setting and identifies important parameters for reliable tissue TMB assessment that require careful control. As complex or composite biomarkers beyond TMB are likely playing an increasing role in therapy prediction, the efforts by QuIP and Friends of Cancer Research also delineate a general framework and blueprint for the evaluation of such assays., (Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
16. Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity.
- Author
-
Dávalos-Salas M, Montgomery MK, Reehorst CM, Nightingale R, Ng I, Anderton H, Al-Obaidi S, Lesmana A, Scott CM, Ioannidis P, Kalra H, Keerthikumar S, Tögel L, Rigopoulos A, Gong SJ, Williams DS, Yoganantharaja P, Bell-Anderson K, Mathivanan S, Gibert Y, Hiebert S, Scott AM, Watt MJ, and Mariadason JM
- Subjects
- Animals, Calorimetry, Diet, High-Fat, Fatty Acids metabolism, Gene Deletion, Gene Expression Regulation, Intestinal Mucosa metabolism, Lipid Peroxidation genetics, Lipidomics, Mice, Mitochondria metabolism, Peroxisome Proliferator-Activated Receptors agonists, Peroxisome Proliferator-Activated Receptors genetics, Triglycerides metabolism, Enterocytes metabolism, Histone Deacetylases genetics, Lipid Metabolism genetics, Obesity genetics
- Abstract
Histone deacetylase 3 (Hdac3) regulates the expression of lipid metabolism genes in multiple tissues, however its role in regulating lipid metabolism in the intestinal epithelium is unknown. Here we demonstrate that intestine-specific deletion of Hdac3 (Hdac3
IKO ) protects mice from diet induced obesity. Intestinal epithelial cells (IECs) from Hdac3IKO mice display co-ordinate induction of genes and proteins involved in mitochondrial and peroxisomal β-oxidation, have an increased rate of fatty acid oxidation, and undergo marked remodelling of their lipidome, particularly a reduction in long chain triglycerides. Many HDAC3-regulated fatty oxidation genes are transcriptional targets of the PPAR family of nuclear receptors, Hdac3 deletion enhances their induction by PPAR-agonists, and pharmacological HDAC3 inhibition induces their expression in enterocytes. These findings establish a central role for HDAC3 in co-ordinating PPAR-regulated lipid oxidation in the intestinal epithelium, and identify intestinal HDAC3 as a potential therapeutic target for preventing obesity and related diseases.- Published
- 2019
- Full Text
- View/download PDF
17. DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
- Author
-
Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, and Mariadason JM
- Subjects
- Animals, Carcinogenesis pathology, Cell Line, Tumor, CpG Islands genetics, Down-Regulation genetics, Gene Expression Regulation, Neoplastic genetics, Humans, Intestines pathology, MAP Kinase Signaling System genetics, Mice, Mice, Transgenic, Phenotype, Promoter Regions, Genetic genetics, Carcinogenesis genetics, Cell Proliferation genetics, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, DNA Methylation genetics, Dual-Specificity Phosphatases genetics
- Abstract
The ERK signalling pathway regulates key cell fate decisions in the intestinal epithelium and is frequently dysregulated in colorectal cancers (CRCs). Variations in the dynamics of ERK activation can induce different biological outcomes and are regulated by multiple mechanisms, including activation of negative feedback loops involving transcriptional induction of dual-specificity phosphatases (DUSPs). We have found that the nuclear ERK-selective phosphatase DUSP5 is downregulated in colorectal tumours and cell lines, as previously observed in gastric and prostate cancer. The DUSP5 promoter is methylated in a subset of CRC cell lines and primary tumours, particularly those with a CpG island methylator phenotype (CIMP). However, this epigenetic change alone could not account for reduced DUSP5 expression in CRC cells. Functionally, DUSP5 depletion failed to alter ERK signalling or proliferation in CRC cell lines, and its transgenic overexpression in the mouse intestine had minimal impact on normal intestinal homeostasis or tumour development. Our results suggest that DUSP5 plays a limited role in regulating ERK signalling associated with the growth of colorectal tumours, but that methylation the DUSP5 gene promoter can serve as an additional means of identifying CIMP-high colorectal cancers.
- Published
- 2018
- Full Text
- View/download PDF
18. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
- Author
-
Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau AK, and Mariadason JM
- Subjects
- Animals, Azepines pharmacology, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Drug Synergism, Gene Expression Regulation, Neoplastic drug effects, HCT116 Cells, Humans, Mice, Neoplasm Transplantation, Proto-Oncogene Proteins c-myc metabolism, Pyridones pharmacology, Pyrimidinones pharmacology, Triazoles pharmacology, Xenograft Model Antitumor Assays, Azepines administration & dosage, Colorectal Neoplasms drug therapy, MAP Kinase Signaling System drug effects, Proto-Oncogene Proteins c-myc genetics, Pyridones administration & dosage, Pyrimidinones administration & dosage, Triazoles administration & dosage, Wnt Signaling Pathway drug effects
- Abstract
Inhibitors of the bromodomain and extraterminal domain (BET) protein family attenuate the proliferation of several tumor cell lines. These effects are mediated, at least in part, through repression of c-MYC. In colorectal cancer, overexpression of c-MYC due to hyperactive WNT/β-catenin/TCF signaling is a key driver of tumor progression; however, effective strategies to target this oncogene remain elusive. Here, we investigated the effect of BET inhibitors (BETi) on colorectal cancer cell proliferation and c-MYC expression. Treatment of 20 colorectal cancer cell lines with the BETi JQ1 identified a subset of highly sensitive lines. JQ1 sensitivity was higher in cell lines with microsatellite instability but was not associated with the CpG island methylator phenotype, c-MYC expression or amplification status, BET protein expression, or mutation status of TP53, KRAS/BRAF, or PIK3CA/PTEN Conversely, JQ1 sensitivity correlated significantly with the magnitude of c-MYC mRNA and protein repression. JQ1-mediated c-MYC repression was not due to generalized attenuation of β-catenin/TCF-mediated transcription, as JQ1 had minimal effects on other β-catenin/TCF target genes or β-catenin/TCF reporter activity. BETi preferentially target super-enhancer-regulated genes, and a super-enhancer in c-MYC was recently identified in HCT116 cells to which BRD4 and effector transcription factors of the WNT/β-catenin/TCF and MEK/ERK pathways are recruited. Combined targeting of c-MYC with JQ1 and inhibitors of these pathways additively repressed c-MYC and proliferation of HCT116 cells. These findings demonstrate that BETi downregulate c-MYC expression and inhibit colorectal cancer cell proliferation and identify strategies for enhancing the effects of BETi on c-MYC repression by combinatorial targeting the c-MYC super-enhancer. Mol Cancer Ther; 15(6); 1217-26. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
19. The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.
- Author
-
Shin J, Carr A, Corner GA, Tögel L, Dávalos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, and Mariadason JM
- Published
- 2015
- Full Text
- View/download PDF
20. The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.
- Author
-
Shin J, Carr A, Corner GA, Tögel L, Dávalos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, and Mariadason JM
- Subjects
- Alkaline Phosphatase genetics, Benzamides pharmacology, Binding Sites genetics, Blotting, Western, Butyric Acid pharmacology, Cell Differentiation genetics, Cell Line, Tumor, Colonic Neoplasms genetics, Colonic Neoplasms metabolism, Colonic Neoplasms pathology, CpG Islands genetics, DNA Methylation, Drug Resistance, Neoplasm genetics, Gene Expression Profiling, HCT116 Cells, HT29 Cells, Humans, Kruppel-Like Transcription Factors genetics, Oligonucleotide Array Sequence Analysis, Promoter Regions, Genetic genetics, Protein Binding, Pyridines pharmacology, Reverse Transcriptase Polymerase Chain Reaction, Alkaline Phosphatase metabolism, Cell Differentiation drug effects, Epithelial Cells metabolism, Histone Deacetylase Inhibitors pharmacology, Kruppel-Like Transcription Factors metabolism
- Abstract
The histone deacetylase inhibitor (HDACi) sodium butyrate promotes differentiation of colon cancer cells as evidenced by induced expression and enzyme activity of the differentiation marker intestinal alkaline phosphatase (ALPi). Screening of a panel of 33 colon cancer cell lines identified cell lines sensitive (42%) and resistant (58%) to butyrate induction of ALP activity. This differential sensitivity was similarly evident following treatment with the structurally distinct HDACi, MS-275. Resistant cell lines were significantly enriched for those harboring the CpG island methylator phenotype (p = 0.036, Chi square test), and resistant cell lines harbored methylation of the ALPi promoter, particularly of a CpG site within a critical KLF/Sp regulatory element required for butyrate induction of ALPi promoter activity. However, butyrate induction of an exogenous ALPi promoter-reporter paralleled up-regulation of endogenous ALPi expression across the cell lines, suggesting the presence or absence of a key transcriptional regulator is the major determinant of ALPi induction. Through microarray profiling of sensitive and resistant cell lines, we identified KLF5 to be both basally more highly expressed as well as preferentially induced by butyrate in sensitive cell lines. KLF5 overexpression induced ALPi promoter-reporter activity in resistant cell lines, KLF5 knockdown attenuated butyrate induction of ALPi expression in sensitive lines, and butyrate selectively enhanced KLF5 binding to the ALPi promoter in sensitive cells. These findings demonstrate that butyrate induction of the cell differentiation marker ALPi is mediated through KLF5 and identifies subsets of colon cancer cell lines responsive and refractory to this effect., (© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
21. Resident CD8(+) and migratory CD103(+) dendritic cells control CD8 T cell immunity during acute influenza infection.
- Author
-
Waithman J, Zanker D, Xiao K, Oveissi S, Wylie B, Ng R, Tögel L, and Chen W
- Subjects
- Acute Disease, Animals, Dendritic Cells immunology, Female, Humans, Mice, Antigens, CD metabolism, CD8-Positive T-Lymphocytes immunology, Cell Movement immunology, Dendritic Cells cytology, Dendritic Cells metabolism, Influenza A virus physiology, Integrin alpha Chains metabolism, Orthomyxoviridae Infections immunology
- Abstract
The identification of the specific DC subsets providing a critical role in presenting influenza antigens to naïve T cell precursors remains contentious and under considerable debate. Here we show that CD8(+) T lymphocyte (TCD8+) responses are severely hampered in C57BL/6 mice deficient in the transcription factor Batf3 after intranasal challenge with influenza A virus (IAV). This transcription factor is required for the development of lymph node resident CD8(+) and migratory CD103(+)CD11b(-) DCs and we found both of these subtypes could efficiently stimulate anti-IAV TCD8+. Using a similar ex vivo approach, many publications on this subject matter excluded a role for resident, non-migratory CD8(+) DC. We postulate the differences reported can partially be explained by how DC are phenotyped, namely the use of MHC class II to segregate subtypes. Our results show that resident CD8(+) DC upregulate this marker during IAV infection and we advise against its use when isolating DC subtypes.
- Published
- 2013
- Full Text
- View/download PDF
22. Villin expression is frequently lost in poorly differentiated colon cancer.
- Author
-
Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, and Mariadason JM
- Subjects
- Animals, Biomarkers, Tumor genetics, Cell Differentiation physiology, Cell Membrane metabolism, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, DNA Methylation genetics, DNA, Neoplasm genetics, Down-Regulation, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Homeodomain Proteins metabolism, Humans, Kaplan-Meier Estimate, Mice, Mice, SCID, Microfilament Proteins genetics, Microsatellite Instability, Microsatellite Repeats, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Neoplasm Transplantation, Oligonucleotide Array Sequence Analysis methods, Prognosis, Promoter Regions, Genetic genetics, Real-Time Polymerase Chain Reaction methods, Tumor Cells, Cultured, Biomarkers, Tumor metabolism, Colorectal Neoplasms metabolism, Microfilament Proteins metabolism
- Abstract
Colorectal cancers (CRCs) are classified as having microsatellite instability (MSI) or chromosomal instability (CIN); herein termed microsatellite stable (MSS). MSI colon cancers frequently display a poorly differentiated histology for which the molecular basis is not well understood. Gene expression and immunohistochemical profiling of MSS and MSI CRC cell lines and tumors revealed significant down-regulation of the intestinal-specific cytoskeletal protein villin in MSI colon cancer, with complete absence in 62% and 17% of MSI cell lines and tumors, respectively. Investigation of 577 CRCs linked loss of villin expression to poorly differentiated histology in MSI and MSS tumors. Furthermore, mislocalization of villin from the membrane was prognostic for poorer outcome in MSS patients. Loss of villin expression was not due to coding sequence mutations, epigenetic inactivation, or promoter mutation. Conversely, in transient transfection assays villin promoter activity reflected endogenous villin expression, suggesting transcriptional control. A screen of gut-specific transcription factors revealed a significant correlation between expression of villin and the homeobox transcription factor Cdx-1. Cdx-1 overexpression induced villin promoter activity, Cdx-1 knockdown down-regulated endogenous villin expression, and deletion of a key Cdx-binding site within the villin promoter attenuated promoter activity. Loss of Cdx-1 expression in CRC lines was associated with Cdx-1 promoter methylation. These findings demonstrate that loss of villin expression due to Cdx-1 loss is a feature of poorly differentiated CRCs., (Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
23. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction.
- Author
-
Wilson AJ, Chueh AC, Tögel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M, Smartt HJ, Murray LB, Nicholas C, Heerdt BG, Arango D, Augenlicht LH, and Mariadason JM
- Subjects
- Apoptosis genetics, Apoptosis physiology, Binding Sites, Butyrates pharmacology, Caco-2 Cells, Colonic Neoplasms enzymology, Colonic Neoplasms pathology, Dactinomycin pharmacology, HCT116 Cells, HT29 Cells, Humans, Kruppel-Like Factor 4, Kruppel-Like Transcription Factors genetics, Kruppel-Like Transcription Factors metabolism, Promoter Regions, Genetic, Sp1 Transcription Factor metabolism, Sp3 Transcription Factor metabolism, Transcriptional Activation, Apoptosis drug effects, Colonic Neoplasms drug therapy, Colonic Neoplasms genetics, Gene Expression Regulation, Neoplastic drug effects, Genes, Immediate-Early drug effects, Histone Deacetylase Inhibitors pharmacology, Sp1 Transcription Factor genetics, Sp3 Transcription Factor genetics
- Abstract
Histone deacetylase inhibitors (HDACi) induce growth arrest and apoptosis in colon cancer cells and are being considered for colon cancer therapy. The underlying mechanism of action of these effects is poorly defined with both transcription-dependent and -independent mechanisms implicated. We screened a panel of 30 colon cancer cell lines for sensitivity to HDACi-induced apoptosis and correlated the differences with gene expression patterns induced by HDACi in the five most sensitive and resistant lines. A robust and reproducible transcriptional response involving coordinate induction of multiple immediate-early (fos, jun, egr1, egr3, atf3, arc, nr4a1) and stress response genes (Ndrg4, Mt1B, Mt1E, Mt1F, Mt1H) was selectively induced in HDACi sensitive cells. Notably, a significant percentage of these genes were basally repressed in colon tumors. Bioinformatics analysis revealed that the promoter regions of the HDACi-induced genes were enriched for KLF4/Sp1/Sp3 transcription factor binding sites. Altering KLF4 levels failed to modulate apoptosis or transcriptional responses to HDACi treatment. In contrast, HDACi preferentially stimulated the activity of Spl/Sp3 and blocking their action attenuated both the transcriptional and apoptotic responses to HDACi treatment. Our findings link HDACi-induced apoptosis to activation of a Spl/Sp3-mediated response that involves derepression of a transcriptional network basally repressed in colon cancer.
- Published
- 2010
- Full Text
- View/download PDF
24. Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.
- Author
-
Brázdová M, Quante T, Tögel L, Walter K, Loscher C, Tichý V, Cincárová L, Deppert W, and Tolstonog GV
- Subjects
- Binding Sites, Cell Line, Tumor, Chromatin metabolism, Chromatin Immunoprecipitation, DNA, Intergenic chemistry, Genome, Human, Glioblastoma genetics, Humans, Sequence Analysis, DNA, Tumor Suppressor Protein p53 genetics, DNA, Intergenic metabolism, Gene Expression Regulation, Neoplastic, Genes, p53, Introns, Mutation, Missense, Tumor Suppressor Protein p53 metabolism
- Abstract
Missense point mutations in the TP53 gene are frequent genetic alterations in human tumor tissue and cell lines derived thereof. Mutant p53 (mutp53) proteins have lost sequence-specific DNA binding, but have retained the ability to interact in a structure-selective manner with non-B DNA and to act as regulators of transcription. To identify functional binding sites of mutp53, we established a small library of genomic sequences bound by p53(R273H) in U251 human glioblastoma cells using chromatin immunoprecipitation (ChIP). Mutp53 binding to isolated DNA fragments confirmed the specificity of the ChIP. The mutp53 bound DNA sequences are rich in repetitive DNA elements, which are dispersed over non-coding DNA regions. Stable down-regulation of mutp53 expression strongly suggested that mutp53 binding to genomic DNA is functional. We identified the PPARGC1A and FRMD5 genes as p53(R273H) targets regulated by binding to intronic and intra-genic sequences. We propose a model that attributes the oncogenic functions of mutp53 to its ability to interact with intronic and intergenic non-B DNA sequences and modulate gene transcription via re-organization of chromatin.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.